EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation

Nakisa Kamari-Kany iD, Sarah Weischendorff iD, Marianne Ifversen, Denise Elbæk Horan iD, Christian Enevold, Katrine Kielsen iD, Klaus Müller

Pediatric Blood & Cancer · 2025

DOI: 10.1002/pbc.31995 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Blood & Cancer, 2025. Verfasst von Nakisa Kamari-Kany und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Interleukin-1 Receptor-Like 1 Protein, Biomarkers. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The Danish Cancer Society, Danish Childhood Cancer Foundation, Novo Nordisk Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The suppressor of tumorigenesis 2 (ST2) has emerged as one of the most promising biomarkers for predicting mortality of acute graft‐versus‐host disease (aGvHD) when measured at the onset of symptoms, but detailed time course studies are needed to understand the potential of ST2 as a risk marker of both aGvHD and chronic graft‐versus‐host disease (cGvHD), potentially allowing pre‐emptive adjustment of immunosuppressive treatment. Procedure We measured ST2 levels in 117 children undergoing standard hematopoietic stem cell transplantation (HSCT) before conditioning and at regular intervals post‐HSCT.

Results

ST2 levels were significantly increased from Day +7 in patients developing aGvHD of any grade (no GvHD: 23.6 ng/mL; Grade I: 31.9 ng/mL; Grade II: 33.2 ng/mL; Grade III–IV: 59.1 ng/mL; p < 0.0001) and in patients developing aGvHD with visceral involvement (no GvHD: 23.6 ng/mL; skin only aGvHD: 24.9 ng/mL; GI and/or liver aGvHD: 59.8 ng/mL; p < 0.0001). The association between ST2 levels and aGvHD Grade II–IV was confirmed in a multivariable logistic regression analysis, adjusting for diagnosis, conditioning regimen, and donor type (OR = 1.99 per doubling in ST2, 95% confidence interval [CI] = 1.40–2.92; p = 0.00025). Patients developing cGvHD had significantly higher ST2 levels before conditioning and from Day +21 to Day +180 (all p < 0.05). ST2 levels at Day +90 were significantly associated with later development of cGvHD after adjusting for diagnosis, conditioning regimen, donor type, and prior aGvHD (HR = 2.1 per doubling in ST2, 95% CI = 1.51–2.91, p < 0.0001).

Conclusion

This study confirms ST2 as a biomarker reflecting risk of aGvHD and prognosis in pediatric allogeneic HSCT, and our findings indicate a role of ST2 as an early risk marker of cGvHD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationInterleukin-1 Receptor-Like 1 ProteinBiomarkersHumansChildFemaleMaleChild, PreschoolAdolescentChronic DiseaseInfantPrognosisAcute DiseaseTransplantation ConditioningFollow-Up Studies

Stichwörter der Autor:innen

ST2graft‐versus‐host diseasehematopoietic stem cell transplantationpediatrics

Substanzen

Interleukin-1 Receptor-Like 1 ProteinIL1RL1 protein, humanBiomarkers

Autor:innen und Institutionen

  • Department of Pediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Institute For Inflammation Research, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
  • Insitute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark.

ORCID-Profile: Nakisa Kamari-Kany, Sarah Weischendorff, Denise Elbæk Horan, Katrine Kielsen

Förderung

  • The Danish Cancer Society
  • Danish Childhood Cancer Foundation
  • Novo Nordisk Foundation
  • Dagmar Marshall's Foundation
  • Tømrermester Jørgen Holm og Hustru Elisa F. Hansens Mindelegat
  • Børnecancerfonden
  • Novo Nordisk Fonden

Zitieren

APA

Kamari-Kany, N., Weischendorff, S., Ifversen, M., Horan, D. E., Enevold, C., Kielsen, K., & Müller, K. (2025). Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.31995

Vancouver

Kamari-Kany N, Weischendorff S, Ifversen M, Horan DE, Enevold C, Kielsen K, et al. Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation. Pediatric Blood & Cancer. 2025. doi:10.1002/pbc.31995

BibTeX
@article{KamariKany2025,
  author = {Kamari-Kany, Nakisa and Weischendorff, Sarah and Ifversen, Marianne and Horan, Denise Elbæk and Enevold, Christian and Kielsen, Katrine and Müller, Klaus},
  title = {Increased Plasma ST2 Levels Precede the Development of Severe Acute GvHD and Chronic GvHD After Pediatric Hematopoietic Stem Cell Transplantation},
  journal = {Pediatric Blood & Cancer},
  year = {2025},
  doi = {10.1002/pbc.31995}
}
Kostenlos starten →